Safety of Simultaneous Hepatectomy and Splenectomy in the Treatment of Hepatocellular Carcinoma Complicated with Hypersplenism: A Meta-analysis
- PMID: 31485220
- PMCID: PMC6710750
- DOI: 10.1155/2019/9065845
Safety of Simultaneous Hepatectomy and Splenectomy in the Treatment of Hepatocellular Carcinoma Complicated with Hypersplenism: A Meta-analysis
Abstract
Background: We conducted this meta-analysis to compare the efficacy and safety of simultaneous hepatectomy and splenectomy (HS) with hepatectomy alone (HA) in patients with hepatocellular carcinoma (HCC) and hypersplenism.
Materials and methods: A systematic search was conducted in PubMed, Embase, Cochrane Library, and Wanfang Data through March 1, 2018, with no limits. Two investigators independently screened all retrieved studies. The investigators of the original publications were contacted if required information was absent. All the included studies were managed by EndNote X7. Quality assessment of the included studies was performed using a modified Newcastle-Ottawa Scale judgment. Extracted data for each endpoint were analyzed by using STATA 12.0 software.
Results: Thirteen studies, including a total of 1468 patients, comparing the effects of HS with HA were pooled in this meta-analysis. Outcomes including postoperative complications, perioperative mortality, intraoperative blood transfusion, and albumin (ALB) content at postoperation day (POD) 7 did not differ significantly between the two groups. Simultaneous approaches significantly promoted 1-, 3-, and 5-year disease-free survival (DFS) rates and overall survival (OS) rates, prolonged operation time, aggravated intraoperative blood loss, increased white blood cell (WBC) and platelet (PLT) counts at POD 7, and lowered total bilirubin (T-Bil) contents at POD 1 and 7.
Conclusion: Compared to HA, HS is safer and more effective in ameliorating liver function and improving survival of HCC patients complicated with hypersplenism. This trial is registered with CRD42018093779.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures



Similar articles
-
Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis.Ann Transl Med. 2021 Apr;9(8):641. doi: 10.21037/atm-20-6748. Ann Transl Med. 2021. PMID: 33987339 Free PMC article.
-
Simultaneous hepatectomy and splenectomy versus hepatectomy alone for hepatocellular carcinoma complicated by hypersplenism: a meta-analysis.Onco Targets Ther. 2015 Aug 19;8:2129-37. doi: 10.2147/OTT.S87580. eCollection 2015. Onco Targets Ther. 2015. PMID: 26316782 Free PMC article.
-
Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A case-control study.World J Gastroenterol. 2015 Feb 28;21(8):2358-66. doi: 10.3748/wjg.v21.i8.2358. World J Gastroenterol. 2015. PMID: 25741142 Free PMC article.
-
Evaluation the efficacy and safety of simultaneous splenectomy in liver transplantation patients: A meta-analysis.Medicine (Baltimore). 2018 Mar;97(10):e0087. doi: 10.1097/MD.0000000000010087. Medicine (Baltimore). 2018. PMID: 29517676 Free PMC article. Review.
-
Laparoscopic Versus Open Hepatectomy in Short- and Long-Term Outcomes of the Hepatocellular Carcinoma Patients with Cirrhosis: A Systematic Review and Meta-Analysis.J Laparoendosc Adv Surg Tech A. 2019 May;29(5):643-654. doi: 10.1089/lap.2018.0588. Epub 2019 Jan 31. J Laparoendosc Adv Surg Tech A. 2019. PMID: 30702362
Cited by
-
Single-cell RNA Sequencing Analysis Reveals New Immune Disorder Complexities in Hypersplenism.Front Immunol. 2022 Jul 5;13:921900. doi: 10.3389/fimmu.2022.921900. eCollection 2022. Front Immunol. 2022. PMID: 35865544 Free PMC article.
-
Activation of MEK-ERK-c-MYC signaling pathway promotes splenic M2-like macrophage polarization to inhibit PHcH-liver cirrhosis.Front Immunol. 2024 Nov 8;15:1417521. doi: 10.3389/fimmu.2024.1417521. eCollection 2024. Front Immunol. 2024. PMID: 39620221 Free PMC article.
-
Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis.Ann Transl Med. 2021 Apr;9(8):641. doi: 10.21037/atm-20-6748. Ann Transl Med. 2021. PMID: 33987339 Free PMC article.
-
The Benefits of Radical Treatments with Synchronous Splenectomy for Patients with Hepatocellular Carcinoma and Portal Hypertension.Cancers (Basel). 2022 Jun 28;14(13):3155. doi: 10.3390/cancers14133155. Cancers (Basel). 2022. PMID: 35804927 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous